Company Conference Call: Reviews Phase 2 Paltusotine Results
Oct 26, 2020 at 8:00 AM EDT
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) held a conference call at 8:00 a.m. Eastern Time today discussing the results of their Phase 2 ACROBAT Edge and ACROBAT Evolve studies of paltusotine (formerly CRN00808), the company’s lead candidate for the treatment of acromegaly.
Company Conference Call: Review of Phase 2 Paltusotine Results
Webcast is currently available for 90 days